← Dashboard
Stock
ABBV
AbbVie Inc.Health CareBiotechnologyLatest close $2146 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
6
27 funds tracked
Ever held
16
Current + past
New this quarter
0
Exited this quarter
0
Marquee-fund ownership over time
Aug 14, 2014May 15, 2018Feb 14, 2022Feb 17, 2026
Now
6
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q1 2021 | 22Q | $86 | $214 | +150% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $182 | $214 | +18% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $182 | $214 | +18% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $182 | $214 | +18% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $182 | $214 | +18% |
| Citadel Advisors | Q4 2024(8Q snapshot) | 6Q | $161 | $214 | +33% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management | Q3 2025 | Q1 2026 | → $231 | +16% |
| Renaissance Technologies | Q3 2024 | Q1 2026 | → $226 | +26% |
| Maverick Capital 6× in & out | Q4 2023 | Q1 2024 | → $161 | +28% |
| Berkshire Hathaway | Q4 2020 | Q2 2022 | → $134 | +69% |
| Coatue Management | Q1 2020 | Q2 2020 | → $72 | -2% |
| Glenview Capital | Q2 2015 | Q2 2018 | → $74 | +76% |
| Duquesne Family Office | Q3 2016 | Q2 2017 | → $46 | +2% |
| Lone Pine Capital | Q4 2014 | Q1 2015 | → $37 | -8% |
| Viking Global Investors | Q4 2014 | Q1 2015 | → $37 | -8% |
| JANA Partners | Q3 2014 | Q1 2015 | → $37 | +10% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at AbbVie Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
11
Filings · last 90d
35
Total on file
585
Recent SEC buffer
Most recent
May 12, 2026
30d / 90d windows measured from May 12, 2026 — the most recent Form 4 on file — not from today.
- Form 40001222890-26-000003May 12, 2026
- Form 40001223690-26-000004May 12, 2026
- Form 40001355580-26-000002May 12, 2026
- Form 40001171780-26-000010May 12, 2026
- Form 40001997505-26-000006May 12, 2026
- Form 40001706126-26-000002May 12, 2026
- Form 40001466338-26-000003May 12, 2026
- Form 40001239126-26-000002May 12, 2026
- Form 40001916665-26-000002May 12, 2026
- Form 40001563579-26-000002May 12, 2026
- Form 40001061632-26-000004May 12, 2026
- Form 40001997505-26-000004Apr 2, 2026
- Form 40001171780-26-000006Apr 2, 2026
- Form 40001448074-26-000007Apr 2, 2026
- Form 4/Aamend0002057696-26-000010Mar 11, 2026
Showing 15 of 585 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · AbbVie Inc.Annual figures sourced directly from AbbVie Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$61.16B
FY2025+9% YoY
Net income
$4.23B
FY2025-1% YoY
EPS (diluted)
$2.36
FY2025-1% YoY
Free cash flow(?)
$17.82B
FY2025-0% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for AbbVie Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KMay 12, 2026
- 10-QQuarterly reportMay 8, 2026
- 8-KMaterial eventApr 29, 2026
- 8-KMaterial eventApr 3, 2026
- DEF 14AProxy statementMar 23, 2026
- 8-KFORM 8-KMar 4, 2026
- 8-KFORM 8-KFeb 26, 2026
- 10-KAnnual reportFeb 20, 2026
- 8-KMaterial eventFeb 4, 2026
- 8-KMaterial eventJan 7, 2026
- 10-QQuarterly reportNov 4, 2025
- 8-KMaterial eventOct 31, 2025
- 8-KMaterial eventOct 3, 2025
- 8-KFORM 8-KSep 11, 2025
- 10-QQuarterly reportAug 4, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q3 2025 | Q1 2026 | $200 | $231 | +16% |
| Citadel Advisors | Q4 2024 | open | $161 | $209 | +30% |
| Two Sigma Investments | Q3 2024 | open | $182 | $209 | +15% |
| D.E. Shaw | Q3 2024 | open | $182 | $209 | +15% |
| AQR Capital Management | Q3 2024 | open | $182 | $209 | +15% |
| Millennium Management | Q3 2024 | open | $182 | $209 | +15% |
| Renaissance Technologies | Q3 2024 | Q1 2026 | $179 | $226 | +26% |
| Maverick Capital | Q4 2023 | Q1 2024 | $127 | $161 | +28% |
| Maverick Capital | Q3 2021 | Q1 2022 | $99 | $123 | +23% |
| Bridgewater Associates | Q3 2021 | open | $98 | $214 | +119% |
| Bridgewater Associates | Q1 2021 | Q2 2021 | $86 | $97 | +13% |
| Berkshire Hathaway | Q4 2020 | Q2 2022 | $80 | $134 | +69% |
| Maverick Capital | Q4 2020 | Q2 2021 | $80 | $97 | +22% |
| Coatue Management | Q1 2020 | Q2 2020 | $73 | $72 | -2% |
| Duquesne Family Office | Q3 2016 | Q2 2017 | $45 | $46 | +2% |
| Maverick Capital | Q2 2016 | Q4 2017 | $41 | $66 | +60% |
| Glenview Capital | Q2 2015 | Q2 2018 | $42 | $74 | +76% |
| Maverick Capital | Q2 2015 | Q4 2015 | $42 | $39 | -8% |
| Lone Pine Capital | Q4 2014 | Q1 2015 | $40 | $37 | -8% |
| Viking Global Investors | Q4 2014 | Q1 2015 | $40 | $37 | -8% |
| Maverick Capital | Q3 2014 | Q1 2015 | $34 | $37 | +10% |
| JANA Partners | Q3 2014 | Q1 2015 | $34 | $37 | +10% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.